SGX301 Demonstrates Positive Benefits for Cutaneous T-Cell Lymphoma
October 22, 2020

Cycle 3 of the FLASH study reported that patients taking SGX301 to treat cutaneous t-cell lymphoma saw improved responses and maintained a positive safety profile.

FDA Approves Expanded Indication of Pembrolizumab for Relapsed/Refractory cHL
October 15, 2020

The FDA approved an expanded label for pembrolizumab (Keytruda) as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

Phase 3 CHRONOS-3 Study Meets Primary End Point for Indolent Non-Hodgkin’s Lymphoma
October 14, 2020

The study is evaluating copanlisib (Aliqopa) in combination with rituximab (Rituxan) in patients with indolent non-Hodgkin’s lymphoma who have relapsed after 1 or more prior lines of rituximab-containing therapy.